Generate a tailored SOP for Dr. Daniel Munblit. Improve your application with a focused, well-structured draft.
Daniel Munblit leads the Core Outcome Measures Food Allergy (COMFA) COST Action, which was approved by EU commissioners in June 2019 and aims to define the scope and applicability of core outcome sets for food allergy. During the COVID-19 pandemic, he led the Stop COVID cohort at Sechenov University in Moscow, Russia, and was heavily involved with the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) in post-COVID condition research, co-leading the ISARIC Global COVID-19 pediatric follow-up. Munblit's research focuses on advocating for stronger regulations in the infant formula industry and has highlighted the issue of commercial influence leading to the overdiagnosis of cow's milk allergy in England. A recent study he contributed to revealed that infant formula products often make unsubstantiated health and nutritional claims, which has been reported in a publication in the BMJ. He serves as an Associate Editor for the Clinical & Experimental Allergy journal and is a member of various committees within the World Allergy Organization (WAO) and the European Academy of Allergy and Clinical Immunology (EAACI), where he has also served on the Pediatric section board. Munblit has provided expert commentary for mass media outlets including The Guardian, BBC, and Sky News, discussing topics related to his areas of expertise.
King's College London • London, UK
Leading research on food allergies and pediatric health.
Requirements are consistent across King's Business School and Social Science & Public Policy departments for standard Master's entries.